Drugs / ALG-020572
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05001022 | Sep 2021 → Jul 2022 | chronic hepatitis B virus infection | Aligos Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2022-03-22 | Aligos Therapeutics | Results Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio aligos.com ↗ |
| 2021-11-12 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B (CHB) and Nonalcoholic Steatohepatitis (NASH) Portfolio at The Liver Meeting® 2021 aligos.com ↗
Aligos’ ASO therapeutic candidate ALG-020572 was shown to potently inhibit HBsAg in vitro and in vivo. |
| 2021-02-03 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data for its Chronic Hepatitis B Drug Candidates at the 30th Annual Conference of the Asian Pacific Association for the Study of the Liver aligos.com ↗
Three of the presentations highlight encouraging data from Aligos’ two most advanced CHB candidates for development toward a combination therapy for chronic hepatitis B (CHB): STOPS™ (ALG-010133), a proprietary oligonucleotide designed to inhibit hepatitis B virus (HBV) S-antigen (or HBsAg) replication, and ALG-000184, a capsid assembly modulator (CAM), designed to inhibit HBV replication. |
| 2020-11-16 | Aligos Therapeutics | Results Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD’s The Liver Meeting Digital Experience™ 2020 aligos.com ↗
ALG-020572, which targets the open reading frame (ORF) of the small HBsAg, demonstrates excellent in vivo potency and safety profiles in an AAV-HBV mouse efficacy model. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALG-020572 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05001022 ↗ |
| Route | Subcutaneous | “Subcutaneous injections of ALG-020572” NCT05001022 ↗ |